2011
Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study
Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study. Clinical Cancer Research 2011, 17: 1147-1159. PMID: 21220480, PMCID: PMC3074404, DOI: 10.1158/1078-0432.ccr-10-1869.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsDrug-Related Side Effects and Adverse ReactionsErbB ReceptorsFemaleGefitinibHumansMiddle AgedNeoplasms, Hormone-DependentPlacebosQuinazolinesReceptor, ErbB-2Receptors, EstrogenSignal TransductionTamoxifenTreatment OutcomeConceptsAdjuvant aromatase inhibitorsMetastatic breast cancerBreast cancerHormone receptor-positive metastatic breast cancerPositive metastatic breast cancerRandomized phase II studyRandomized phase II trialClinical benefit ratePhase II studyPhase II trialProgression-free survivalStratum 1Epidermal growth factor receptor inhibitor gefitinibFurther investigationAdjuvant tamoxifenImproved PFSPFS HRAI therapyII studyII trialMetastatic diseaseAppropriate patientsPredictive biomarkersPrimary tumorTamoxifen resistance
2006
AQUA and FISH analysis of HER‐2/neu expression and amplification in a small cell lung carcinoma tissue microarray
Giltnane JM, Murren JR, Rimm DL, King BL. AQUA and FISH analysis of HER‐2/neu expression and amplification in a small cell lung carcinoma tissue microarray. Histopathology 2006, 49: 161-169. PMID: 16879393, DOI: 10.1111/j.1365-2559.2006.02479.x.Peer-Reviewed Original ResearchConceptsNeu gene amplificationProtein expression levelsProtein expressionPoor prognosisNeu expressionTissue microarraySmall cell lung carcinoma patientsAQUA scoreHER-2/neu expressionGene amplificationCell lung carcinoma patientsTumor cellsSCLC tumor cellsSCLC tumor progressionHER-2/neu protein expressionMetastatic breast cancerTime of diagnosisLimited treatment optionsLung carcinoma patientsBreast cancer casesHER-2/neu geneNeu protein expressionExpression levelsGene copy numberMetastatic disease
2000
A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome
Camp R, Rimm E, Rimm D. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer 2000, 88: 108-113. PMID: 10618612, DOI: 10.1002/(sici)1097-0142(20000101)88:1<108::aid-cncr15>3.0.co;2-b.Peer-Reviewed Original ResearchConceptsTumor-free lymph nodesLymph node negative breast carcinomaNode-negative breast carcinomaNegative breast carcinomaFree lymph nodesLymph nodesBreast carcinomaPrognostic valueTumor-free axillary lymph nodesTumor-negative lymph nodesDetectable lymph nodesNegative lymph nodesAxillary lymph nodesLymph node hyperplasiaLymph node metastasisReliable prognostic indicatorPresence of necrosisAxillary resectionLymphovascular invasionMetastatic diseasePatient ageIndependent predictorsLymphocytic infiltrateNode metastasisAggressive disease
1999
Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma
Camp R, Rimm E, Rimm D. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999, 86: 2259-2265. PMID: 10590366, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2259::aid-cncr13>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsAxillary lymph node negative breast carcinomaLymph node negative breast carcinomaExpression of METNode-negative breast carcinomaNegative breast carcinomaBreast carcinomaMET expressionMetastatic diseaseRelative riskNegative invasive ductal carcinomaLow Met expressionMET-negative patientsIndependent predictive valueIndependent prognostic markerUseful prognostic indicatorInvasive ductal carcinomaStandard immunoperoxidase techniqueHigh MET expressionHepatocyte growth factorActivation of METAxillary lymphNegative patientsPatient agePrognostic factorsAggressive disease
1995
Reduced alpha-catenin and E-cadherin expression in breast cancer.
Rimm DL, Sinard JH, Morrow JS. Reduced alpha-catenin and E-cadherin expression in breast cancer. Laboratory Investigation 1995, 72: 506-12. PMID: 7745946.Peer-Reviewed Original ResearchConceptsE-cadherinSteady-state levelsE-cadherin expressionHomotypic cell adhesion proteinMetastatic diseaseCell adhesion proteinsHuman E-cadherinCell-cell interactionsCytoplasmic proteinsTime of biopsyAdhesion proteinsAggressive tumor behaviorAdhesive functionEffector elementsAdhesion cascadeAbsent E-cadherin expressionTypes of cancerJunctional complexesProteinBreast cancerEpithelial tumorsSensitive markerTumor behaviorExpressionCancer